No Data
H.C. Wainwright Initiates Sutro Biopharma(STRO.US) With Hold Rating, Announces Target Price $2
Sutro Biopharma Analyst Ratings
Sutro Biopharma Announces Poster Presentations To Highlight Its Next-Generation Exatecan And Dual-Payload ADC Programs At Upcoming American Association for Cancer Research April 25-30 In Chicago, Illinois
Sutro Biopharma to Highlight Its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Lacklustre Performance Is Driving Sutro Biopharma, Inc.'s (NASDAQ:STRO) 36% Price Drop
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn